The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021

Life Sciences M&A Was Almost Half Of 2019’s Record

COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.

fire embers
Biopharma companies have ample deal-making "firepower" to deploy in 2021

The pandemic may have deterred biopharma deal-making, particularly large-scale deals, during 2020 but the industry retains significant firepower heading into 2021, a new report from EY says. Issued on 11 January, the first day of the virtual J.P. Morgan Healthcare Conference, EY’s report notes that there was $159bn of life sciences M&A activity last year, down from $306bn in 2019, a record-setting year.

Biopharmaceutical companies only used 12% of their aggregate firepower – defined by EY’s life sciences business development group as capacity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza